Lake Street keeps Avita Medical at Buy and lifts target to $20
Lake Street kept its Buy rating on Avita Medical and raised the price target to $20 from $12, according to Dow Jones Newswires citing Benzinga data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Lake Street has kept its Buy rating on Avita Medical shares and raised its price target to $20.00 per share from $12.00. The update was reported by Dow Jones Newswires, citing Benzinga's ratings data.
why it matters
A single broker's rating change usually affects only the stock itself and says little about the broader market. For Avita Medical investors, it signals a higher valuation from Lake Street.
tags
instruments
sources
- Avita Medical Is Maintained at Buy by Lake Street — Dow Jones Newswires, 7 November 2026 at 01:45 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗